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Abstract 26 
In the United-Kingdom about 1 in 2000 people could be infected with variant Creutzfeldt-27 
Jakob Disease (vCJD). The risk of transmission of vCJD by medical procedures therefore 28 
remains a major concern for public health authorities. 29 
In this study, we used in vitro amplification of prions by Protein Misfolding Cyclic 30 
Amplification (PMCA) to estimate the distribution and the level of the vCJD agent in a range 31 
of tissues (n=21) from four patients who died with clinical vCJD and from one asymptomatic 32 
vCJD-infected individual.  33 
Unexpectedly, PMCA demonstrated the presence of significant levels of vCJD prions in a 34 
wide range of tissues, including liver, salivary gland, kidney, lung or bone marrow. Bioassays 35 
confirmed that the quantitative estimate of vCJD prion accumulation levels provided by 36 
PMCA are indicative of vCJD infectivity levels in tissues.  37 
This work provides critical data for the design of rational measures aimed at minimising the 38 
risk of iatrogenic transmission of vCJD.  39 
  40 
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Introduction 41 
Prion diseases, or transmissible spongiform encephalopathies (TSEs), are fatal 42 
neurodegenerative disorders that occur naturally in sheep (scrapie), cattle (bovine spongiform 43 
encephalopathy - BSE), and humans (Creutzfeldt-Jakob disease - CJD). A key event in the 44 
pathogenesis of TSEs is the conversion of the normal cellular prion protein (PrP
C
, encoded by 45 
PRNP) into an abnormal disease-associated isoform (PrP
Sc
) in tissues of infected individuals. 46 
PrP
C
 is completely degraded after controlled digestion with proteinase K (PK) in the presence 47 
of non-denaturing detergents. In contrast, PrP
Sc 
is N-terminally truncated under the same 48 
conditions, leaving a PK resistant core, termed PrP
res 
(1).  49 
In 1996, a new form of CJD, termed variant CJD (vCJD) was identified in the UK, which is 50 
believed to result from zoonotic transmission of the BSE agent, probably as a consequence of 51 
dietary exposure to BSE-contaminated meat products (2, 3). The total number of clinical cases 52 
of vCJD identified thus far is limited (227 patients worldwide at the time of writing). 53 
However, the estimated prevalence of asymptomatic vCJD infection in populations exposed 54 
to the BSE agent  is uncertain (4). In the UK 32,441 appendix samples, collected during 55 
surgery on patients born between 1941 and 1985 have been tested for abnormal prion protein 56 
accumulation by immunohistochemistry. This study gave a vCJD prevalence estimate of 1 in 57 
2,000 in these age cohorts (95% Confidence Interval ranging from 1 in 3,500 to 1 in 1,250) 58 
(5). There is no comparable data available concerning the prevalence of asymptomatic vCJD 59 
infection in other countries, although BSE exposure is known to have occurred in several 60 
continental European counties, as judged by cases of vCJD that are not attributable to 61 
exposure in the UK (http://www.cjd.ed.ac.uk/documents/worldfigs.pdf).  62 
Over the last two decades several studies have reported on the distribution of the vCJD agent 63 
in the tissues of infected patients (6-8). Most have failed to detect the vCJD agent outside the 64 
nervous system (central, peripheral and autonomic) and lymphoid tissues. However, the 65 
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sensitivity of the PrP
res
 detection techniques used in these historical investigations was 66 
limited.  67 
The Protein Misfolding Cyclic Amplification (PMCA) is thought to mimic prion replication 68 
in vitro, but in an accelerated form, allowing amplification of minute amounts of PrP
Sc
 and 69 
prion infectivity (9). In PMCA, a PrP
C
-containing “substrate” is combined with a “seed” that 70 
may contain otherwise undetectable amounts of PrP
Sc
. Following repeated cycles of 71 
incubation and sonication, the amount of PrP
Sc 
increases to levels at which they can be 72 
detected by conventional biochemical means. Recently, we and others have shown that 73 
PMCA is able to detect endogenous vCJD agent present in patient biological fluids such as 74 
urine and blood (10, 11).  75 
In this study, we first evaluated the relative sensitivity of the PMCA assay versus bioassay in 76 
mice for the detection of the vCJD agent. We then estimated, using PMCA, the level of vCJD 77 
prions in 21 tissues collected from patients who died with symptomatic vCJD (n=4) and from 78 
a patient with an asymptomatic vCJD infection. Finally, we determined whether the vCJD 79 
prion levels as estimated by PMCA were consistent with the infectious titres as estimated by 80 
bioassay using transgenic mice.  81 
82 
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Methods 83 
Ethics Statement 84 
All animal experiments were performed in compliance with institutional and French national 85 
guidelines and in accordance with the European Community Council Directive 86/609/EEC. 86 
The animal experiments that are part of this study (national registration 01734.01) were 87 
approved by the local ENVT ethic committee. Mouse inoculations were performed under 88 
anaesthesia (isofulorane). Mice that displayed clinical signs were anesthetized with 89 
isofluorane before sacrifice using CO2 inhalation.  90 
Human samples were obtained from the UK National CJD Research & Surveillance Unit 91 
Brain and Tissue Bank, which is part of the MRC Edinburgh Brain Bank. Tissue samples 92 
were pseudo-anonymized using a Brain Bank reference number. All UK cases had informed 93 
consent for research and their supply and use in this study was covered by the East of 94 
Scotland Research Ethics Service approval for the Edinburgh Brain Bank (16/ES/0084). 95 
 96 
vCJD and control patients 97 
Tissues from four clinical vCJD cases (referred to in this study as vCJD-1 to vCJD-4) and one 98 
asymptomatic vCJD- infected individual who received a transfusion of packed red blood cells 99 
from a donor who subsequently died from vCJD (12) (vCJD-A) were investigated. Tissues 100 
from two non-vCJD infected patients (NC-1 and NC-2) were used as controls. Basic 101 
demographic details for the vCJD and control patients are presented in table 3. In cases with 102 
appropriate consent, the entire PRNP coding sequence was established as to exclude 103 
pathogenic mutations in the PRNP gene (13, 14). Table 4 shows the tissue tested from each 104 
patient. 105 
 106 
Mouse bioassays 107 
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Bioassay was carried out using mice expressing bovine PrP (tgBov-Tg100) as previously 108 
described (15, 16). These mice were observed daily and their neurological status was assessed 109 
weekly. When clinically progressive TSE symptoms were evident, or at the end of their 110 
lifespan, the animals were euthanized. Survival time was expressed as the mean of the days 111 
post inoculation (dpi) of all the mice scored positive for PrP
res
, with a corresponding standard 112 
deviation. In cages where no clinical signs were observed, mice were sacrificed at the end of 113 
their natural life-span (600 to 800 days). In those cases, incubation periods reported in the 114 
table as >600 dpi, corresponded to the survival time observed in at least three out of the six 115 
mice.  116 
 117 
Infectious prion titre estimates 118 
The infectious titre in a reference 10% weight/vol frontal cortex homogenate from a clinical 119 
vCJD patient was established by endpoint titration (intracerebral route) in tgBov mice. The 120 
infectious titre (LD50/g IC in tgBov) was estimated by the Spearman method.  121 
The titre of prion infectivity in vCJD affected patients bone marrow samples was estimated 122 
using the method developed by Arnold et al. (17). This model uses both the probability of 123 
survival (attack rate at each dilution) and the individual mouse incubation periods at each 124 
dilution to estimate infectious load and is thus able to provide more accurate estimation of 125 
titre than using either attack rate or incubation period data alone.  126 
 127 
PMCA reactions 128 
A transgenic mouse line that expresses ovine A136R154Q171 PrP variant PrP
C
 (tgShXI) was 129 
used to prepare the PMCA substrate as previously described (18, 19). PMCA amplification 130 
was performed as previously described (11). Each PMCA run included a reference vCJD 131 
sample (10% brain homogenate) as a control for the amplification efficiency. Unseeded 132 
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controls (1 unseeded control for 8 seeded reactions) were also included in each run. For each 133 
tested dilution of each sample, at least four replicates were tested in two independent runs. For 134 
each sample, the last dilution showing at least 50% of positive replicates (presence of 135 
detectable PrP
res
 in the reaction as assessed by WB) was determined. 136 
 137 
Abnormal PrP Western blot (WB) detection  138 
PK resistant abnormal PrP extraction (PrP
res
) and Western blot were performed as previously 139 
described (11). Immunodetection was performed using two different monoclonal PrP-specific 140 
antibodies, Sha31 (1 µg/ml) (20), and 12B2 (4 µg/ml) (21), which recognize the amino acid 141 
sequences YEDRYYRE (145-152), and WGQGG (89-93) respectively.  142 
 143 
Paraffin embedded tissue blot  144 
Paraffin embedded tissue was performed as previously described (22, 23). 145 
  146 
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Results  147 
Sensitivity of vCJD agent detection by PMCA and bioassay  148 
In order to determine the relative sensitivity of PMCA, a reference sample (10% cerebral 149 
cortex homogenate from a vCJD affected patient) that had previously undergone end point 150 
titration (IC inoculation route –sup table 1) in bovine PrP expressing mice (tgBov) was re-151 
titrated by PMCA.  152 
The amplification of a ten-fold serial dilution of this sample (6 individual replicates per 153 
dilution point) demonstrated that four PMCA rounds (24 hours per round i.e. 96 hours) were 154 
sufficient to reach the maximal sensitivity level of the assay. Additional PMCA rounds 155 
improved neither the analytical sensitivity of the assay nor the number of positive replicates 156 
(table 2 –figure 1). Based on thes  results, the seeding activity (SA) of the isolate was 157 
estimated by the Spearman method to be 10
11
 SA50 per gram. The bioassay end point titration 158 
data of the same sample in tgBov gave an infectious titre of 10
7.7
 LD50 per gram. Taking into 159 
account the 4 fold lower amount of material used to seed the PMCA reaction compared to the 160 
material used in mouse inoculations, these results indicate that the PMCA protocol we used 161 
was 465 times more sensitive than bioassay in tgBov mice for the detection of vCJD prions.  162 
 163 
PMCA results in control and vCJD affected patients 164 
A ten-fold dilution series of the 10% homogenates from the vCJD affected and non-vCJD 165 
control patients was then prepared (table 3) and these were subjected to four rounds of 166 
PMCA. The amplification products from each round were tested for the presence of PrP
res
 by 167 
Western Blot (table 4 and figure 2).  168 
None of the reactions seeded with tissue homogenates from the non-CJD controls were found 169 
to be positive for PrP
res
 (table 4). In contrast, the PMCA reactions seeded with tissues from 170 
the four symptomatic vCJD patients were found to be positive for PrP
res
 (table 4- figure 2). As 171 
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expected, among the tested tissues, the brain homogenates (temporal cortex) showed the 172 
highest seeding activity (last PrP
res
 positive dilution 10
-8
). All of the tested lymphoid organs 173 
also displayed seeding activity, but the last PMCA positive dilution varied according to the 174 
tested organs from 10
-2
 (thymus) to 10
-6
 (distal ileum and tonsil). Moreover, for a given 175 
lymphoid organ, up to a 10
2
 fold differences was observed in seeding activity, depending on 176 
the patient and sample tested.  Taken together these data indicate that in symptomatic vCJD 177 
patients the lymphoid organs contain between 10
2
 and 10
6
 fold less prion seeding activity than 178 
the same amount of brain tissue (table 4). 179 
 180 
Salivary gland, adrenal gland, liver and bone marrow from the four symptomatic vCJD 181 
patients gave positive reactions in PMCA (figure 2 and 3). Using the last dilution to show a 182 
positive reaction as a measure of the seeding activity, the vCJD agent in these tissue was 183 
found to be 10
3
 to 10
6 
fold lower than that found in the brain. PrP
res
 was also detected in 184 
PMCA reactions seeded with heart, liver, kidney, skeletal muscle, several endocrine/exocrine 185 
glands (pancreas, thyroid) and the gonads, from some, but not all, of the four clinical vCJD 186 
patients. Where positive, these tissue contained a level of vCJD seeding activity that was 187 
equivalent to those observed in distal ileum (i.e 10
3
 to 10
6
 fold lower than in the brain). 188 
Irrespective of the tissue used to seed the PMCA reactions, the PrP
res
 Western blot profile in 189 
positive reactions was indistinguishable from that observed in reactions seeded with the vCJD 190 
brain control (figure 3).  191 
 192 
Analysis of tissues from an asymptomatic vCJD-infected individual 193 
No prion seeding activity was detected in the brain (temporal cortex) of this asymptomatic 194 
vCJD infected patient, who was a PRNP codon 129 heterozygote (Met/Val129) (12) (table 4, 195 
figure 2). PMCA reactions seeded with dorsal root ganglia or trigeminal ganglia homogenates 196 
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from this patient also tested negative. However, seeding activity was detected in the pituitary 197 
gland (last PrP
res
 positive dilution 10
-2
). Additionally, as with the symptomatic vCJD patients, 198 
PMCA amplification readily detected the presence of vCJD prions in all of the tested 199 
lymphoid organs in this asymptomatic individual. According to the PMCA results, the vCJD 200 
agent load in lymphoid organs in this PRNP codon 129 Met/Val129 asymptomatic patient were 201 
similar to those observed in the Met/Met129 patients at the clinical stage of the disease. In 202 
addition to the lymphoid organs, prion seeding activity was detectable in certain peripheral 203 
tissues from this patient (notably salivary gland, lung and liver) (table 4, figure 2 and 3). 204 
Strikingly, certain tissues that contained a substantial prion seeding activity in the clinically 205 
affected patients (such as bone marrow or the adrenal gland) were found to be negative. 206 
Again, the PrP
res
 Western blot profile in positive reactions was indistinguishable from that 207 
observed in reactions seeded with the vCJD brain control 208 
 209 
vCJD infectivity in bone marrow 210 
In order to test whether the PMCA seeding activity in peripheral tissues of vCJD patients 211 
correlated to the presence of infectivity, the bone marrow samples from the symptomatic 212 
patient were inoculated to tgBov mice. A clinical TSE was observed in mice that were 213 
inoculated with each of the four bone marrow samples. The PrP
res
 Western blot profile and the 214 
PrP
res 
distribution pattern as assessed by PET Blot in the brain of the bone marrow-inoculated 215 
mice were identical to those observed in tgBov mice inoculated with the vCJD brain control 216 
(figure 4).  217 
The data collected in mice inoculated with the bone marrow samples were also used to 218 
estimate prion infectivity levels in these samples. For this purpose, we applied the method 219 
developed by Arnold et al. (17). The approach combines the probability of survival (attack 220 
rate) and the individual mouse incubation period to provide an estimation of the infectious 221 
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titres. Data corresponding to endpoint titration in tgBov mice of the reference vCJD sample 222 
(frontal cortex from a clinical vCJD patient) (table 1) were used to derive the relationship 223 
between the prion titre of inoculum and the probability of infection and the length of the 224 
incubation period (figure 5). According to this model the bone marrow samples displayed an 225 
infectious titre that was estimated to range between 10
2.3
 and 10
4.7
 LD50/g in tgBov (table 5).   226 
These values are consistent with a 10
3
 to 10
5
 lower infectivity load in bone marrow samples 227 
than in the reference vCJD brain sample. Interestingly, and in keeping with the PMCA results 228 
(table 4), the prion load in bone marrow samples (last PrP
res 
positive dilution 10
-3
 to 10
-5
) were 229 
also 10
3
 to 10
5
 fold lower than in this reference vCJD isolate (last PrP
res 
positive dilution 10
-8
). 230 
Taken together these results strongly support the contention that the PMCA seeding activity 231 
provides a reliable estimate of the prion load in the tissues of vCJD-infected patients. 232 
 233 
  234 
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Discussion 235 
While most of the previous investigations carried out on tissue from vCJD patients have failed 236 
to identify consistent accumulation of the vCJD agent outside the nervous and the lympho-237 
reticular systems, the data obtained in this study clearly demonstrate the presence of vCJD 238 
prions in a wide and unexpected variety of peripheral tissues.  239 
Natural scrapie and experimental BSE in sheep are two models of orally transmitted prion 240 
diseases (24, 25). In both diseases, the agent accumulates in the lympho-reticular system and 241 
in the enteric nervous system during the early preclinical phase of the incubation period. 242 
Moreover, an early and persistent prionemia is observed in asymptomatic infected animals 243 
(26, 27). These features were also observed in vCJD in humans and in view of the likely 244 
origin of vCJD (oral exposure to BSE agent), these similarities have led to a consensus that 245 
BSE and scrapie in sheep and vCJD in human share a common pathogenesis (28). 246 
While the presence of vCJD prions in a variety tissues such as bone marrow, kidney, salivary 247 
gland, the skeletal muscle, the pancreas, the liver or the heart might appear surprising, each of 248 
these tissue has already been demonstrated to accumulate prion infectivity and/or abnormal 249 
prion protein in TSE infected sheep (29-33). Since low levels of infectivity have been 250 
reported in blood fractions from a vCJD affected patient, it might be argued such widespread 251 
tissue positivity derives from residual blood, rather than from the solid tissue in these samples 252 
(16). However, this seems very unlikely given the fact that in whole blood the presence of 253 
PMCA amplification inhibitors preclude the detection of endogenous vCJD agent by this 254 
methodology (11, 34-36).  255 
The PRNP codon 129 Met/Val case included in this study is one of only two identified vCJD-256 
infected individuals known to have died of other causes before the onset clinical symptoms of 257 
vCJD, and the only case with consent to sample autopsy tissues for research. In this patient, 258 
all previous investigations failed to show the presence of abnormal prion protein or infectivity 259 
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in the brain (12, 37). The negative PMCA results we obtained using the cerebral cortex, the 260 
dorsal root ganglia and the trigeminal ganglia tissue from this patient are consistent with a 261 
lack of CNS involvement at the time of death. However, the presence of PMCA seeding 262 
activity in the pituitary gland is surprising in this regard.  263 
The presence of abnormal prion protein accumulation in the pituitary gland and other 264 
circumventricular organs prior to deposition of PrP
res
 in surrounding brain is a phenomenon 265 
that has been reported in TSE infected sheep (38). However, this phenomenon in animals does 266 
not seem to represent the main route for neuro-invasion and it is a likely consequence of 267 
haematogenous dissemination of the TSE agent through the fenestrated capillary system of 268 
the circumventricular organs, which is substantially more permeable than the other capillaries 269 
in the brain (the “blood-brain barrier”). This finding may therefore be a consequence of the  270 
haematogenous route of secondary vCJD infection in this individual (via transfusion of 271 
packed red blood cells from a vCJD-infected donor), in contrast to the  oral route of infection 272 
in the primary clinical vCJD cases (12). 273 
 274 
vCJD prions were detected in certain peripheral tissues from this PRNP codon 129 Met/Val 275 
patient. Although the distribution of the vCJD seeding activity in the lymphoreticular tissues 276 
was similar to that observed in the symptomatic vCJD patients, a number of tissues that were 277 
positive in clinically affected patients were negative in this heterozygous asymptomatic 278 
individual. These findings suggest that the involvement of some peripheral tissues might 279 
occur at a later stage in the incubation period than others, or that they could involve 280 
recirculation of the agent from the CNS (i.e centrifugal spread at a late state). However, we 281 
cannot discount the possibility that that these differences in tissue distribution are due to 282 
either the haematogenous route of infection in this individual (as opposed to the likely oral 283 
route in the clinical vCJD cases) or the difference between the PRNP codon 129 genotype of 284 
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the asymptomatic vCJD infected individual (PRNP codon 129 Met/Val) and the clinical vCJD 285 
cases (PRNP codon 129 Met/Met) 286 
 287 
Irrespective of the actual explanation for these differences, the presence of vCJD agent in 288 
peripheral tissues of patients at both preclinical and clinical stage of the disease indicates the 289 
potential for iatrogenic transmission of this fatal neurological condition by surgical 290 
procedures. Furthermore, it shows that for certain peripheral tissues a level of infectivity 291 
equivalent to an end stage titre (and attendant risk) is reached at a pre-clinical stage.  292 
Several hundred cases of iatrogenic CJD have been reported worldwide. These cases appear 293 
to result from the transmission of sporadic CJD (sCJD) and most cases have occurred in the 294 
recipients of human dura mater grafts or the administration of human growth hormone 295 
extracted from cadaveric pituitaries (39). While in sCJD the distribution of the agent is largely 296 
restricted to the nervous system (central and peripheral), the wide distribution of the vCJD 297 
agent in the asymptomatic infected patient we describe here may serve to increase the range 298 
of medical procedures that might result in the iatrogenic transmission of vCJD (including 299 
dentistry, organ transplant, surgery involving non-disposable equipment) (40-43). 300 
Nevertheless, more than 20 years after the identification of the first vCJD patients, only five 301 
cases that are a likely consequence of iatrogenic vCJD transmission have come to light, all in 302 
the UK and all associated with blood and blood products. These cases were due to either the 303 
transfusion of non-leukodepleted red cell concentrates, or with treatment involving large 304 
amounts of pooled UK plasma that were known to include donations from individuals who 305 
later developed vCJD (12, 44-46). None of the 220 other vCJD cases identified worldwide 306 
have been linked to any other medical or dental procedure. Whilst reassuring, it would be 307 
unwise to disregard the threat that vCJD still poses for public health. Despite the relatively 308 
low number of vCJD clinical cases observed in the United Kingdom (n=178), the most recent 309 
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epidemiological studies indicate that 1 out 2000 people in the UK could carry the vCJD agent 310 
(as judged by the presence of abnormal prion protein detected by immunohistochemistry in 311 
lymphoid follicles in the appendix). Each asymptomatic vCJD-infected person represents a 312 
potential source of secondary infection. The data we reported here offers an opportunity for 313 
refining the measures that were implemented in many countries to limit the risk of vCJD 314 
iatrogenic transmission. The apparent concordance between the PMCA biochemical and 315 
infectivity bioassay data, and the higher analytical sensitivity of PMCA suggest that future 316 
research need not rely exclusively on time-consuming and costly animal bioassay. 317 
Our results clearly highlight the need for vCJD screening assays. After more than a decade of 318 
effort several vCJD blood detection tests have reached a stage in their development that could 319 
permit their evaluation as screening or confirmatory assays (11, 47, 48). In particular, there is 320 
now a very strong case for the use of PMCA in a highly sensitive and specific blood test for 321 
vCJD as judged by our previous work (11, 16) and the very recent publications by Concha-322 
Marambio et al and Bougard et al (35, 36) . The relationship shown here between PrP
res
 323 
amplification by PMCA and the detection of infectivity by bioassay argues that PMCA 324 
seeding activity is a good surrogate marker of infectivity, and could provide a sound basis for 325 
a vCJD blood test for use on blood or tissue donors.  326 
 327 
  328 
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Table 1: Endpoint titration of a reference vCJD sample (10% weight volume frontal cortex homogenate) in mice expressing the bovine PrP 472 
(tgBov) 473 
 474 
 
 
Transmission in tgBov 
Dilution 
 
Pos mice 
Incubation 
(mean±SD) 
neat  6/6 249±2 days 
10
-1
  6/6 283±15 days 
10
-2
  6/6 316±21 days 
10
-3
  6/6 342±10 days 
10
-4
  6/6 453±66 days 
10
-5
  2/6 479, 495 days*  
10
-6
  1/6 502 days*  
10
-7
  0/6 >700 days  
 475 
A 10% weight/volume homogenate was prepared using frontal cortex from a clinically affected vCJD patient. Groups of 6 tgBov mice were 476 
inoculated intracerebrally with 20µL of serial ten-fold dilutions of this homogenate. Mice were considered positive when abnormal PrP 477 
deposition was detected in the brain. Incubation periods are presented as mean +/-SD, except for those marked (*) indicating dilutions in which 478 
less than half of mice were scored as positive. 479 
 480 
  481 
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Table 2: Endpoint titration of the PMCA seeding activity in a reference vCJD brain sample  482 
 483 
 
 
Reference vCJD 10% brain homogenate dilution series  
number of positive PMCA reactions  
Amplification  
round 
 
10
-2
 10
-3
 10
-4
 10
-5
 10
-6
 10
-7
 10
-8
 10
-9
 10
-10
 
1  6/6 6/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 
2  6/6 6/6 5/6 3/6 0/6 0/6 0/6 0/6 0/6 
3  6/6 6/6 6/6 6/6 3/6 0/6 0/6 0/6 0/6 
4  6/6 6/6 6/6 6/6 6/6 5/6 2/6 0/6 0/6 
5  6/6 6/6 6/6 6/6 6/6 5/6 2/6 0/6 0/6 
6  6/6 6/6 6/6 6/6 6/6 5/6 2/6 0/6 0/6 
 484 
10% weight/volume homogenate was prepared using frontal cortex from a symptomatic vCJD patient (using the same homogenate as in table 1).  485 
Samples were serially diluted ten-fold (10
-2
 to 10
-10
) before being used to seed PMCA reactions. Six individual replicates of each sample dilution 486 
were tested. The PMCA substrate was prepared using brains from transgenic mice over-expressing the ARQ variant of the sheep prion protein. 487 
Reactions were then subjected to 6 amplification rounds, each composed of 96 cycles (10s sonication-14 minutes and 50 seconds incubation at 488 
39.5°C) in a Qsonica700. After each round, (i) reaction products (1 volume) were mixed with fresh substrate (9 volumes) to seed the following 489 
round while (ii) a part of the same product was analysed by Western Blot (WB) for the presence of PK resistant PrP (PrP
res
 -antibody Sha31 490 
epitope YEDRYYRE). The number of PrP
res
 WB positive replicates corresponding to each round and each dilution are reported. 491 
 492 
  493 
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Table 3: Characteristics of the patients included in the study 494 
 495 
Patient 
Identifier 
Diagnosis Gender 
Year of 
death 
Age at death  
Disease 
duration  
PRNP 
codon 129 
PRNP mutations 
vCJD-1 vCJD M 1999 33 years 18 months MM No mutations detected 
vCJD-2 vCJD F 2000 17 years 18 months MM No mutations detected 
vCJD-4 vCJD M 2000 26 years 10 months MM No mutations detected 
vCJD-3 vCJD M 2001 26 years 10 months MM No mutations detected 
vCJD-A Asymptomatic vCJD  F 2004 82 years N/A MV No mutations detected 
NC-1 
Not CJD (tumour, infarction, 
ischaemia) 
F 2005 85 years  N/A MM No consent for sequencing 
NC-2 
Not CJD (Alzheimer’s disease, 
infarction, ischaemia) 
F 2010 80 years N/A MM No mutations detected 
 496 
 497 
  498 
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Table 4: Results of Protein Misfolding Cyclic Amplification reactions seeded with tissue homogenate from vCJD and control patients  499 
  
vCJD clinical  
(Met129/Met129) 
 
vCJD preclinical  
(Met129/Val129) 
 
Non vCJD controls 
(Met129/Met129) 
Tissue  vCJD-1 vCJD-2 vCJD-3 vCJD-4  vCJD-A  NC-1 NC-2 
           
Frontal cortex  10
-8
 10
-8
 10
-8
 10
-8
  neg  neg neg 
Pituitary gland  N/A N/A N/A N/A  10
-2
  neg neg 
Trigeminal ganglia  N/A N/A N/A N/A  neg  neg neg 
Dorsal root ganglia  N/A N/A N/A N/A  neg  neg neg 
           
Cervical Lymph 
node 
 10
-5
 10
-4
 10
-4
 10
-3
  10
-4
  NA NA 
Tonsil  10
-3
 10
-4
 10
-6
 10
-3
  10
-3
  NA neg 
Appendix  10
-4
 10
-4
 10
-4
 10
-3
  10
-2
  neg neg 
Distal Ileum   10
-3
 10
-5
 10
-5
 10
-2
  10
-3
  neg neg 
Spleen  10
-4
 10
-4
 10
-5
 10
-4
  10
-3
  neg neg 
Thymus  NA 10
-3
 10
-2
 10
-2
  10
-2
  NA NA 
           
Lung  10
-2
 10
-2
 neg neg  10
-3
  neg neg 
Heart  10
-2
 10
-2
 neg neg  neg  neg neg 
Liver   10
-4
 10
-2
 10
-2
 10
-4
  10
-2
  neg neg 
           
Kidney  10
-2
 10
-3
 neg 10
-3
  neg  neg neg 
Salivary gland  10
-4
 10
-3
 10
-2
 10
-3
  10
-2
  neg neg 
           
Pancreas  10
-2
 neg 10
-2
 10
-4
  neg  neg neg 
Thyroid  10
-2
 neg 10
-2
 10
-2
  neg  neg neg 
Adrenal gland  10
-3
 10
-3
 10
-3
 10
-4
  neg  neg neg 
           
Bone marrow  10
-4
 10
-5
 10
-3
 10
-4
  neg  neg neg 
           
Skeletal muscle  10
-4
 10
-2
 neg N/A  neg  neg neg 
           
Testis  neg NA neg 10
-3
  N/A  N/A N/A 
Ovary  N/A 10
-4
 N/A N/A  N/A  N/A N/A 
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PMCA reactions were seeded with ten-fold serial dilutions of vCJD 10% tissues homogenates (10
-2
 to 10
-9
) that had been collected post mortem 500 
from symptomatic vCJD patients (vCJD-1 to vCJD-4) or an asymptomatic vCJD-infected individual (vCJD-A). At least four replicates of each 501 
sample dilution were tested in two independent PMCA runs. 502 
vCJD-1 to vCJD-4 were homozygous for methionine at codon 129 of the PRNP gene. Patient vCJD-A was heterozygous (methionine/valine) at 503 
codon 129 of the PRNP gene. The PMCA substrate was prepared using brains from transgenic mice over-expressing the ARQ variant of the 504 
sheep prion protein. Reactions seeded with tissues from two non-vCJD infected control patients (NC-1 and NC-2) were included as negative 505 
controls. PMCA reactions were then subjected to 4 amplification rounds each comprising 96 cycles (10s sonication-14 minutes and 50 seconds 506 
incubation at 39.5°C) in a Qsonica700. The PMCA reactions were analysed by Western Blot (WB) for the presence of PK resistant PrP (PrP
res
 -507 
antibody Sha31 epitope YEDRYYRE). The last positive dilution that resulted in a positive WB signal in at least half of the tested replicates after 508 
4 PMCA amplification rounds is reported in the table. N/A denotes not applicable. Neg denotes negative.  509 
 510 
  511 
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Table 5: Bone marrow sample bioassay in bovine PrP expressing mice (tgBov) 512 
 513 
 
 
Transmission in tgBov 
 
Infectious titer (LD50/g) 
Mean – (CI 95%) 
case 
 Positive/inoculated 
mice 
Incubation 
(mean±SD) 
 
vCJD-1  5/5 458±37 days  10
3.1
 (10
2.6
-10
3.5
) 
vCJD-2  6/6 373±35 days   10
4.7
 (10
4.3
-10
5.2
) 
vCJD-3  4/6 504±10 days  10
2.3
 (10
1.8
-10
2.7
) 
vCJD-4  6/6 447±91 days  10
4.0
 (10
3.4
-10
4.5
) 
PBS control  0/6 >600 days  N/A 
 514 
10% weight/volume bone marrow homogenates prepared from four symptomatic vCJD patients (see table 3) was inoculated intracerebrally (IC) 515 
into 6 tgBov mice (20µL per mouse). One mouse (inoculated with vCJD-1) died within the first few days following IC inoculation. Mice were 516 
euthanized when they showed clinical signs of prion infection or after 600 days post inoculation.  Mice were considered prion infected when 517 
abnormal PrP deposition was detected in brain. Infectious prion titres were estimated using the method developed by Arnold et al. (17). The 518 
model uses both the probability of survival (attack rate at each dilution) and the individual mouse incubation periods at each dilution to estimate 519 
the infectious load. Infectious titres are given as the estimated value and, in parentheses, the lower and upper limits of the 95% confidence 520 
intervals.  521 
 522 
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Figures: 523 
Figure 1: PMCA amplification of vCJD PrP
res
  524 
PMCA reactions were seeded with a ten-fold serial dilutions of a reference vCJD brain 525 
homogenate (10% weight / volume -10
-2
 to 10
-10
 dilution). This homogenate had been 526 
endpoint titrated previously by bioassay in bovine PrP expressing mice (tgBov, intracerebral 527 
route – 10
7.7
 DL50/g). 528 
PMCA substrate was prepared using brains from transgenic mice over-expressing the ARQ 529 
variant of the sheep prion protein. Unseeded reactions were included as specificity control. 530 
PMCA reactions were then subjected to 6 rounds of amplification, each comprising 96 cycles 531 
(10s sonication-14 minutes and 50 seconds incubation at 39.5°C) in a Qsonica700. After each 532 
round, (i) reaction products (1 volume) were mixed with fresh substrate (9 volumes) to seed 533 
the following round while (ii) a part of the same product was analysed by Western Blot (WB) 534 
for the presence of abnormal PK resistant PrP (PrP
res
 -antibody Sha31 epitope YEDRYYRE).  535 
A sheep scrapie in sample was included as control on each gel (WB control). 536 
 537 
Figure 2: vCJD Protein Misfolding Cyclic Amplification in peripheral tissues  538 
PMCA reactions were seeded with a ten-fold dilution series of vCJD tissues homogenates (10
-
539 
2
 to 10
-9
) that had been collected post mortem from a vCJD-infected patient at clinical stage or 540 
preclinical stage of the disease. At least four replicates of each sample dilution were tested in 541 
two independent PMCA runs. 542 
Patients (a) vCJD-1, (b) vCJD-2, (c) vCJD-3 and (d) vCJD-4 died with clinical vCJD. These 543 
four patients were homozygotes Methionine at codon 129 of the PRNP gene. Patient (e) 544 
vCJD-A died while at an asymptomatic or preclinical stage of the disease. This patient was 545 
heterozygous Methionine/Valine at codon 129 of the PRNP gene. 546 
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PMCA substrate was prepared using brains from transgenic mice over-expressing the ARQ 547 
variant of the sheep prion protein. Unseeded reactions and reaction seeded with tissues from 548 
two non-vCJD infected control patients (NC-1 and NC-2 see table 3) were included as a 549 
specificity control. PMCA reactions were then subjected to 4 amplification rounds each 550 
comprising 96 cycles (10s sonication-14 minutes and 50 seconds incubation at 39.5°C) in a 551 
Qsonica700. After each round, (i) reaction products (1 volume) were mixed with fresh 552 
substrate (9 volumes) to seed the following round while (ii) a part of the same product was 553 
analysed by Western Blot (WB) for the presence of abnormal PK resistant PrP (PrP
res
 -554 
antibody Sha31 epitope YEDRYYRE).  555 
For each round, the last dilution displaying a positive WB signal in at least half of the tested 556 
replicates is indicated on the graph. (○): round 1 - () : round 2 - (): round 3 - (): round 4. 557 
 558 
Figure 3: PrP
res
 WB detection in PMCA reactions seeded with peripheral tissues  559 
PMCA reactions were seeded with a ten-fold dilution series (10
-2
 to 10
-9
) of vCJD tissues 560 
homogenates that had been collected post mortem from vCJD patients at clinical stage 561 
(symptomatic vCJD case 1 to vCJD case 4) or at an asymptomatic or preclinical stage of the 562 
disease (vCJD asymp.) (see table 2). Reactions seeded with tissues from two non-vCJD 563 
patients (see table 2) and unseeded PMCA reactions were included as specificity controls. 564 
Reactions were then subjected to 4 amplification rounds each comprising 96 cycles (10s 565 
sonication-14 minutes and 50 seconds incubation at 39.5°C) in a Qsonica700.  566 
The PMCA reactions were analysed by Western Blot (WB) for the presence of abnormal PK 567 
resistant PrP (PrP
res
 -antibody Sha31 epitope YEDRYYRE). On each gel (i) a scrapie in sheep 568 
isolate and a vCJD reference isolate were used as control (WB cont.). 569 
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For the seven presented tissues (frontal cortex, appendix, lung, liver, salivary gland, pancreas 570 
and bone marrow) the dilution of the tissues homogenates used to seed the PMCA reactions is 571 
indicated below the immunoblots. 572 
 573 
574 
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Figure 4: PrP
res
 detection by Western Blot (WB) and Paraffin Embedded Tissue blot 575 
(PET blot), in the brain of transgenic mice expressing the bovine-PrP (tgBov). 576 
(a) PrP
res
 WB of (i) a vCJD sample (frontal cortex) and of tgBov mice (brain) inoculated with 577 
(ii) the same vCJD reference isolate or (iii) with bone marrow samples from vCJD affected 578 
patients( vCJD 1 to 4 see table 2)  and non vCJD control (NC-1, see table 2). On each gel a 579 
scrapie isolate (WB cont.) and a non-inoculated tgBov brain homogenate were included as 580 
controls. PrP
res
 immunodetection was carried out using Sha31 monoclonal antibody (epitope: 581 
145YEDRYYRE152) and 12B2 epitope (epitope 89WGQGG93). 582 
(b) PET blot PrP
res
 distribution in coronal section (thalamus level) of tgBov mice inoculated 583 
with a reference vCJD isolate (10% brain homogenate) or bone marrow (10% tissue 584 
homogenate) from two vCJD pati nts at clinical stage of the disease (vCJD-1 and vCJD-3 see 585 
table 2).  PrP
res
 immunodetection was carried out using Sha31 monoclonal antibody (epitope: 586 
145YEDRYYRE152 ). Bar: 120µm. 587 
 588 
Figure 5: Dose-response relationship for the incubation period and probability of 589 
infection of bovine PrP expressing mice. 590 
Data derived from an endpoint titration of 10% weight/volume frontal cortex homogenate 591 
from a vCJD affected patient in tg Bov mice (20µL intracerebral route, see table 1) were used 592 
to establish a model that estimates the infectious titre in an homogenate based on the 593 
incubation period and the probability of infection in inoculated mice (model is solid line, 594 
observed values given by crosses). 595 
 596 
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Abstract 26 
In the United Kingdom about 1 in 2000 people could be infected with variant Creutzfeldt-27 
Jakob-Disease (vCJD). In that context, the risk of transmission of vCJD by medical 28 
procedures remains a major concern for public health authorities. 29 
In this study, in vitro amplification of prions by the Protein Misfolding Cyclic Assay (PMCA) 30 
was used to estimate the distribution and the level of vCJD agent in a range of tissues (n=21) 31 
from four patients who died with clinical vCJD and one asymptomatic vCJD-infected 32 
individual.  33 
Unexpectedly, PMCA demonstrated the presence of significant levels of vCJD prions in 34 
numerous tissues, including liver, salivary gland, kidney, lung or bone marrow. Bioassays 35 
confirmed that the quantitative estimate of vCJD prion accumulation levels provided by 36 
PMCA are indicative of the vCJD infectivity levels in peripheral tissues.  37 
This work provides critical data for the design of rational measures aimed at minimising the 38 
risk of iatrogenic transmission of vCJD.  39 
. 40 
  41 
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Introduction 42 
Prion diseases, or transmissible spongiform encephalopathies (TSEs), are fatal 43 
neurodegenerative disorders that occur naturally in sheep (scrapie), cattle (bovine spongiform 44 
encephalopathy - BSE), and humans (Creutzfeldt-Jakob disease - CJD). A key event in the 45 
pathogenesis of TSEs is the conversion of the normal cellular prion protein (PrP
C
, which is 46 
encoded by PRNP) into an abnormal disease-associated isoform (PrP
Sc
) in tissues of infected 47 
individuals. PrP
C
 is completely degraded after controlled digestion with proteinase K (PK) in 48 
the presence of non-denaturing detergents. PrP
Sc 
is N-terminally truncated under such 49 
conditions, leaving a PK resistant core, termed PrP
res 
(1).  50 
In 1996, a new form of CJD, termed variant CJD (vCJD) was identified in the UK and is 51 
believed to be due to zoonotic transmission of the agent that causes BSE in cattle, probably as 52 
a consequence of dietary exposure to BSE-contaminated meat products (2, 3).  53 
The total number of vCJD clinical cases identified so far remains limited (227 patients 54 
worldwide at the time of writing). However, the prevalence of asymptomatic vCJD infection 55 
in populations exposed to the BSE agent remains extremely uncertain (4). In the UK 32,441 56 
appendix samples, collected during surgery on patients born between 1941 and 1985 were 57 
tested for abnormal prion protein accumulation by immunohistochemistry. This study 58 
indicated a likely vCJD prevalence estimate of 1 in 2,000 in these age cohorts (95% 59 
Confidence Interval ranging from 1 in 3,500 to 1 in 1,250) (5). Outside the UK, there is no 60 
data available concerning the prevalence of asymptomatic vCJD infection in the population, 61 
although BSE exposure is likely to have occurred in several continental European counties as 62 
judged by cases of vCJD in these counties which have no known link to BSE exposure in the 63 
UK (http://www.cjd.ed.ac.uk/documents/worldfigs.pdf)  64 
Over the last two decades a substantial number of studies have focused on the distribution of 65 
the vCJD agent in the tissues of infected patients (6-8). Most have failed to demonstrate a 66 
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convincing accumulation of the vCJD agent outside the nervous system (central, peripheral 67 
and autonomic) and lymphoid tissues. However, the sensitivity of the PrP
res
 detection 68 
techniques used in these investigations was limited.  69 
The Protein Misfolding Cyclic Amplification (PMCA) technology is thought to mimic prion 70 
replication in vitro but in accelerated form, allowing amplification of minute amounts of PrP
Sc
 71 
and prion infectivity (9). It is facilitated by combining a PrP
C
-containing substrate with a seed 72 
comprising a tissue homogenate containing previously undetectable amounts of PrP
Sc
. By 73 
repetitive cycles of incubation and sonication, the levels of PrP
Sc 
in the seed are increased to 74 
levels at which they can be detected by conventional biochemical techniques. Recently the 75 
capacity of PMCA to detect endogenous vCJD agents present at very low levels in biological 76 
fluids such as urine and blood from infected patients has been shown to be possible (10, 11).  77 
In this study, we first evaluated the relative sensitivity of the PMCA assay versus bioassay in 78 
mice for the detection the vCJD agent. We then estimated, using PMCA, the level of vCJD 79 
prions in 21 tissues collected post from patients who died with symptomatic vCJD (n=4) and 80 
from a patient with an asymptomatic vCJD infection. Finally we determined whether the 81 
vCJD prion levels as estimated by PMCA were consistent with the infectious titres as 82 
estimated by bioassay using transgenic mice.  83 
84 
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Methods 85 
Ethics Statement 86 
All animal experiments have been performed in compliance with institutional and French 87 
national guidelines, in accordance with the European Community Council Directive 88 
86/609/EEC. The animal experiments that are part of this study (national registration 89 
01734.01) were approved by the ENVT ethic committee. Mouse inoculations were performed 90 
under anaesthesia (isofulorane). Mice that displayed clinical signs were anesthetized with 91 
isofluorane before killing by CO2 inhalation.  92 
Human samples were obtained from the National CJD Research & Surveillance Unit Brain 93 
and Tissue Bank in Edinburgh, UK, which is part of the Edinburgh Brain Bank. For the 94 
purposes of this study, samples w re pseudo-anonymized using a Brain Bank reference 95 
number. All UK cases had informed written consent for research and their supply and use in 96 
this study was covered by Ethics Approval (LREC 2000/4/157). 97 
 98 
Control and vCJD infected patients 99 
Tissues from four clinical vCJD cases (referred to in this study as vCJD-1 to vCJD-4) and one 100 
asymptomatic vCJD- infected individual who received a transfusion of packed red blood cells 101 
from a donor who subsequently died from vCJD (12) (vCJD-A) were investigated. Tissues 102 
from two non-vCJD infected patients (NC-1 and NC-2) were used as control. Information 103 
related to the vCJD and control patients are presented in table 3. In cases with appropriate 104 
consent, the entire PRNP coding sequence was established as to exclude pathogenic mutations 105 
in the PRNP gene (13, 14). Table 4 indicates the list of tissue tested in each patient. 106 
 107 
Mouse bioassays 108 
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Bioassay were carried out in mice expressing the bovine PrP (tgBov-Tg100) as previously 109 
described (15, 16). These mice were observed daily and their neurological status was assessed 110 
weekly. When clinically progressive TSE disease was evident, or at the end of their lifespan, 111 
the animals were euthanized. Survival time was expressed as the mean of the survival days 112 
post inoculation (dpi) of all the mice scored positive for PrP
res
, with a corresponding standard 113 
deviation. In cages where no clinical signs were observed, mice were killed at the end of their 114 
natural life-span (600 to 800 days). In those cases, incubation periods reported in the table 115 
(>600 dpi) corresponded to the survival time observed in at least three out of the six mice.  116 
 117 
Infectious prion titre estimates 118 
The infectious titre in a reference 10% weight/vol temporal cortex homogenate from a clinical 119 
vCJD patient was established by endpoint titration (Intracerebral route) in tgBov mice. The 120 
infectious titre (LD50/g IC in tgBov) was estimated by the Spearman’s method.  121 
The titre of prion infectivity in vCJD affected patients bone marrow samples was estimated 122 
using the method developed by Arnold et al. (17). The model uses both the probability of 123 
survival (attack rate at each dilution) and the individual mouse incubation periods at each 124 
dilution to estimate infectious load and thus is able to provide more accurate estimation of 125 
titre than using either attack rate or incubation period data alone.  126 
 127 
PMCA reactions 128 
A transgenic mouse line that expresses ovine A136R154Q171 PrP variant PrP
C
 (tgShXI) was 129 
used to prepare the PMCA substrate as previously described (18, 19). PMCA amplification 130 
was performed as previously described (11). Each PMCA run included a reference vCJD 131 
sample (10% brain homogenate) as a control for the amplification performance. Unseeded 132 
controls (1 unseeded control for 8 seeded reactions) were also included in each run. For each 133 
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tested dilution of each sample at least four replicates of each these sample dilutions were 134 
tested in two independent run. For each sample the last dilution showing at least 50% of 135 
positive replicates (presence of detectable PrP
res
 in the reaction as assessed by WB) was 136 
determined. 137 
 138 
Abnormal PrP Western blot (WB) detection  139 
PK resistant abnormal PrP extraction (PrP
res
) and Western blot were performed as previously 140 
described (11). Immunodetection was performed using two different monoclonal PrP-specific 141 
antibodies, Sha31 (1 µg/ml) (20), and 12B2 (4 µg/ml) (21) which recognize the amino acid 142 
sequences YEDRYYRE (145-152), and WGQGG (89-93) respectively.  143 
 144 
Paraffin embedded tissue blot  145 
Paraffin embedded tissue was performed as previously described (22, 23). 146 
  147 
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Results  148 
Sensitivity of vCJD agent detection by PMCA and bioassay  149 
In order to determine the relative sensitivity of PMCA, a reference isolate (10% cerebral 150 
cortex homogenate from a vCJD affected patient) that had previously undergone end point 151 
titration (IC inoculation route –sup table 1) in bovine PrP expressing mice (tgBov) was re-152 
titrated by PMCA.  153 
The amplification of a 1/10 dilution series of this sample (6 individual replicates per dilution 154 
point) demonstrated that four PMCA rounds (24 hours per round i.e. 96 hours) were sufficient 155 
to reach the maximal sensitivity level of the assay. Additional PMCA rounds improved 156 
neither the analytical sensitivity of the assay nor the number of positive replicates (table 2 –157 
figure 1). Based on these results, the seeding activity (SA) of the isolate was estimated by the 158 
Spearman’s approach to be 10
10.97
 SA50 per gram. The bioassay end point titration data of the 159 
same isolate in tgBov indicated an infectious titre of 10
7.7
 LD50 per gram. Taking into account 160 
the 4 fold lesser amount of material used to seed a PMCA reaction in comparison to the 161 
material used in mouse inoculations, these results support the contention that PMCA protocol 162 
we used was 465 times more sensitive than bioassay in tgBov mice for the detection of vCJD 163 
prions.  164 
 165 
PMCA results in control and vCJD affected patients 166 
Based on these results, 1/10 dilutions series of the 10% homogenates were prepared from the 167 
tissues collected in vCJD affected and non-vCJD control patients (table 3) before being 168 
subjected to four PMCA amplification rounds. After each amplification round, the PMCA 169 
reaction products were tested for the presence of PrP
res
 by Western Blot (table 4 and figure 2).  170 
None of the reactions seeded with tissues from the non-CJD controls were found to be 171 
positive (table 4). In contrast, the PMCA reactions seeded with numerous tissues from the 172 
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four symptomatic vCJD patients were found to be positive for PrP
res
 (table 4- figure 2). As 173 
expected, among the tested tissues the brain homogenates (temporal cortex) showed the 174 
highest seeding activity (last PrP
res
 positive dilution 10
-8
). All the tested lymphoid organs also 175 
displayed seeding activity, but the last tested PMCA positive dilution varied according to the 176 
tested organs from 10
-2
 (thymus) to 10
-6
 (distal ileum and tonsil). Moreover, for a given 177 
lymphoid organ, up to 10
2
 fold differences were observed in seeding activity depending on the 178 
patient and sample tested.  Taken together these data indicate that in symptomatic vCJD 179 
patients the lymphoid organs contain between 10
2
 and 10
6
 fold less prion seeding activity than 180 
the same amount of brain tissue (table 4). 181 
 182 
In the four symptomatic vCJD patients PrP
res
 was observed in reactions seeded with salivary 183 
gland, adrenal gland, liver and bone marrow (figure 2 and 3). According to the last dilution 184 
showing a seeding activity, the vCJD agent in these tissue was 10
3
 to 10
6 
fold lower than in 185 
the brain. PrP
res
 was also detected in the PMCA reactions seeded with heart, liver, kidney, 186 
skeletal muscle, several endocrine/exocrine glands (pancreas, thyroid) and the gonads, from 187 
some, but not all, of the clinical vCJD patients. Where positive, these tissue contained a level 188 
of vCJD seeding activity that was equivalent to those observed in distal ileum (i.e 10
3
 to 10
6
 189 
fold lower than in the brain).Whichever the tissue used to seed the PMCA reactions, the PrP
res
 190 
western blot profile in positive reactions were indistinguishable from that observed in 191 
reactions seeded with the vCJD brain control (figure 3).  192 
 193 
Analysis of tissues from an asymptomatic vCJD-infected individual 194 
No prion seeding activity was detected in the temporal cortex of this asymptomatic vCJD 195 
infected patient, who was a PRNP codon 129 heterozygote (Met/Val129) (12) (table 4, figure 196 
2). PMCA reactions seeded with the dorsal root ganglia or trigeminal ganglia homogenates 197 
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from this patient were also negative. However, a low seeding activity was detected in the 198 
pituitary gland (last PrP
res
 positive dilution 10
-2
 dilution). Additionally, as with the 199 
symptomatic vCJD patients, PMCA amplification readily detected the presence of vCJD 200 
prions in all the tested lymphoid organs in this asymptomatic individual. According to the 201 
PMCA results, the vCJD agent load in lymphoid organs in this PRNP codon 129 Met/Val 202 
asymptomatic patient were similar to those observed in the Met/Met129 patients at the clinical 203 
stage of the disease. Beside the lymphoid organs, prion seeding activity was present in certain 204 
peripheral tissues from this patient (notably salivary gland, lung and liver) (table 4, figure 2 205 
and 3). Strikingly, certain tissues that contained a substantial prion seeding activity in the 206 
clinically affected patients (such as bone marrow or the adrenal gland) were found to be 207 
negative. Here too, whichever the tissue used to seed the PMCA reactions, the PrP
res
 WB 208 
profile observed in positive reactions was similar to the PrP
res
 WB profile in reaction seeded 209 
with the control vCJD brain (figure 3).  210 
 211 
vCJD infectivity in bone marrow 212 
In order to confirm that the presence of PMCA seeding activity in peripheral tissues of vCJD 213 
patients correlated to the presence of infectivity, the bone marrow samples from the 214 
symptomatic patients used in PMCA experiments were inoculated to tgBov mice. A clinical 215 
TSE was observed in mice that were inoculated with the four bone marrow samples. The 216 
PrP
res
 western blot profile and the PrP
res 
distribution pattern as assessed by PET Blot in the 217 
brain of the bone marrow- inoculated mice were identical to the one observed in tgBov mice 218 
inoculated with the vCJD brain control (figure 4).  219 
The data collected in mice inoculated with the bone marrow samples were also used to 220 
estimate prion infectivity levels in these samples. For this purpose, we applied the method 221 
developed by Arnold et al. (17). The approach combines the probability of survival (attack 222 
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rate) and the individual mouse incubation period to provide an estimation of the infectious 223 
titres. Data corresponding to endpoint titration in tgBov mice of the reference vCJD isolate 224 
(temporal cortex from clinical vCJD patients) (table 1) were used to derive the relationship 225 
between the prion titre of inoculum and the probability of infection and the length of the 226 
incubation period (figure 5). According to this model the bone marrow samples displayed an 227 
infectious titre that estimated to range between 10
2.28
 and 10
4.72
 LD50/g in tgBov (table 5).   228 
These values are consistent with a 10
3
 to 10
5
 lower infectivity load in bone marrow samples 229 
than in the reference vCJD brain isolate. Interestingly, in keeping with the PMCA results 230 
(table 4), the prion load in bone marrow samples (last PrP
res 
positive dilution 10
-3
 to 10
-5
) were 231 
also 10
3
 to 10
5
 folds lower than in this reference vCJD isolate (last PrP
res 
positive dilution 10
-
232 
8
). Taken together these results strongly support the contention that the PMCA seeding 233 
activity provides a reliable estimate of the prion load in the tissues of vCJD-infected patients. 234 
 235 
  236 
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Discussion 237 
While most of the previous investigations carried out on tissue from vCJD patients failed to 238 
identify consistent accumulation of the vCJD agent outside the nervous and the lympho-239 
reticular systems, the data obtained in this study demonstrate the presence of vCJD prions in a 240 
wide and unexpected variety of peripheral tissues.  241 
Natural scrapie and experimental BSE in sheep are two models of orally transmitted prion 242 
diseases (24, 25). In both diseases, the agent accumulates in the lympho-reticular system and 243 
in the enteric nervous system during the early preclinical phase of the incubation period. 244 
Moreover, an early and persistent prionemia is observed in infected but asymptomatic animals 245 
(26, 27). These features were also observed in human vCJD and together with the origin of 246 
vCJD (oral exposure to BSE agent), these similarities progressively led to the consensus that 247 
BSE/scrapie in sheep and vCJD in human share a common pathogenesis (28). 248 
While the presence of vCJD prions in a variety tissues like bone marrow, kidney, salivary 249 
gland, the skeletal muscle, the pancreas, the liver or the heart could seem surprising at first 250 
glance, each of these tissue was demonstrated to accumulate prion infectivity and/or abnormal 251 
prion protein in TSE infected sheep (29-33).  252 
The PRNP codon 129 Met/Val case included in this study is one of only two asymptomatic 253 
vCJD-infected individuals who died before the onset of any clinical symptoms of vCJD, and 254 
the only case with consent to sample autopsy tissues for research. In this patient, all previous 255 
investigations failed to reveal the presence of abnormal prion protein or infectivity in the 256 
brain (12, 34). The results we obtained using the cerebral cortex, the dorsal root ganglia and 257 
the trigeminal ganglia of this patient, as PMCA seeds are consistent with a lack of CNS 258 
involvement by the vCJD agent at the time of death. However, the presence of PMCA seeding 259 
activity in the pituitary gland is perhaps surprising in this context.  260 
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The presence of abnormal prion protein accumulation in the pituitary gland and other 261 
circumventricular organs prior to deposition of PrP
res
 in surrounding brain is a phenomenon 262 
that has been reported in TSE infected sheep(35). However, this phenomenon in animals does 263 
not seem to represent the main route for neuro-invasion and it is a likely consequence of 264 
hematogenous dissemination of the TSE agent through the fenestrated capillary system of the 265 
circumventricular organs that is substantially more permeable than the other capillaries in the 266 
brain (the “blood-brain barrier”). This finding may therefore be a consequence of the likely 267 
haematogenous route of vCJD infection in this individual, via transfusion of packed red blood 268 
cells from a vCJD-infected donor, in contrast to a likely oral route of infection in the clinical 269 
vCJD cases. (12) 270 
 271 
vCJD prions were detected in some peripheral tissues that had been collected in this PRNP 272 
codon 129 Met/Val patient. However, if the distribution of the vCJD seeding activity in the 273 
lymphoreticular tissues was similar to the one observed in the symptomatic vCJD patients, a 274 
number of tissues that had been found positive in clinically affected patients were negative in 275 
this patient. These findings suggest that the involvement of certain peripheral tissues might 276 
occur at a later stage in the incubation period than the one reached by this patient and/or could 277 
involve a recirculation of the agent from the CNS (i.e centrifugal spread at a late state). 278 
However, we cannot discount the possibility that that these differences in tissue distribution 279 
are due to either the likely haematogenous route of infection in this individual (as opposed to 280 
the likely oral route in the clinical vCJD cases) or the difference between the PRNP codon 281 
129 genotype of the asymptomatic vCJD infected individual (PRNP codon 129 Met/Val)  and 282 
the clinical vCJD cases (PRNP codon 129 Met/Met) 283 
 284 
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Irrespective of the explanation for these differences, the presence of vCJD agent in peripheral 285 
tissues of patients at both preclinical and clinical stage of the disease raises the potential 286 
iatrogenic transmission of this fatal neurological condition by medical procedures. 287 
Furthermore, it shows that for certain peripheral tissues end stage titre (and attendant risk) is 288 
reached at a pre-clinical stage.  289 
Several hundred iatrogenic cases of CJD have been reported worldwide. These cases appear 290 
to result from the transmission of sporadic CJD (sCJD) and most cases have occurred in the 291 
recipients of human dura mater grafts or the administration of human growth hormone 292 
extracted from cadaveric pituitaries (36). While in sCJD the distribution of the agent is mainly 293 
restricted to the nervous system (central and peripheral), the wide distribution of the vCJD 294 
agent in asymptomatic but infected patient we described increases the potential number of 295 
medical procedures that might result in the iatrogenic transmission of vCJD (dentistry, organ 296 
transplant, surgery involving non-disposable equipment) (37-40). 297 
Nevertheless, more than 20 years after the identification of the first vCJD patient, only five 298 
cases that are a likely consequence of an iatrogenic vCJD transmission have come to light, all 299 
in the UK. These cases were due to either the transfusion of non-leukodepleted red cell 300 
concentrates or the treatment with large volumes of pooled UK plasma that included 301 
donations from individuals who later developed vCJD (12, 41-43). None of the 220 other 302 
vCJD cases identified worldwide have been linked to any other medical or dental procedure. 303 
 304 
This limited number of vCJD secondary cases identified so far is certainly reassuring. 305 
However, it would be unwise to disregard the threat that vCJD still represents for public 306 
health. Despite the relatively low number of vCJD clinical cases observed so far (n=178) in 307 
the United Kingdom, the most recent epidemiological studies indicate that, 1 out 2000 people 308 
in the UK could carry the vCJD agent (as judged by the presence of abnormal prion protein 309 
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detected by immunohistochemistry in lymphoid follicles in the appendix). Each asymptomatic 310 
vCJD-infected person represents a potential source of secondary transmission of the disease. 311 
In that context, the data we reported here offer an opportunity for refining the measures that 312 
were implemented in many countries to limit the risk of vCJD iatrogenic transmission 313 
occurrence. The apparent concordance of PMCA biochemical and infectivity bioassay data, 314 
and the higher analytical sensitivity of the PMCA assay suggest that future research in this 315 
area need not rely exclusively on time-consuming and costly animal bioassay. 316 
Our results clearly highlight the need for vCJD screening assays. After more than a decade of 317 
effort several vCJD blood detection tests have reached a stage in their development that could 318 
permit their evaluation as screening or confirmatory assays (11, 44, 45). Beyond the ethical 319 
issues that the application of a vCJD screening test would represent (in the absence of any 320 
treatment and the difficulty to confirm a positive test by another methodology in reasonable 321 
time), such assays probably represent the most rational solution for addressing vCJD 322 
iatrogenic transmission risks.   323 
 324 
 325 
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Table 1: Endpoint titration of a reference vCJD isolate (10% weight volume frontal cortex homogenate) in mice expressing the bovine PrP 459 
(tgBov) 460 
 461 
 
 
Transmission in tgBov 
Dilution 
 
Pos mice 
Incubation 
(mean±SD) 
neat  6/6 249±2 days 
10
-1
  6/6 283±15 days 
10
-2
  6/6 316±21 days 
10
-3
  6/6 342±10 days 
10
-4
  6/6 453±66 days 
10
-5
  2/6 479, 495 days*  
10
-6
  1/6 502 days*  
10
-7
  0/6 >700 days  
 462 
A 10% weight/volume homogenate was prepared using frontal cortex from a clinically affected vCJD patient. Groups of 6 tgBov mice were 463 
intracerebrally inoculated with 20µL of successive 1/10 dilutions of this homogenate. Mice were considered positive when abnormal PrP 464 
deposition was detected in the brain. Incubation periods are presented as mean +/-SD, except for those marked (*) indicating dilutions in which 465 
less than half of mice were scored as positive. 466 
 467 
  468 
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Table 2: Endpoint titration of the PMCA seeding activity in a reference vCJD isolate  469 
 470 
 
 
Reference vCJD 10% brain homogenate dilution series  
number of positive PMCA reactions  
Amplification  
round 
 
10
-2
 10
-3
 10
-4
 10
-5
 10
-6
 10
-7
 10
-8
 10
-9
 10
-10
 
1  6/6 6/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 
2  6/6 6/6 5/6 3/6 0/6 0/6 0/6 0/6 0/6 
3  6/6 6/6 6/6 6/6 3/6 0/6 0/6 0/6 0/6 
4  6/6 6/6 6/6 6/6 6/6 5/6 2/6 0/6 0/6 
5  6/6 6/6 6/6 6/6 6/6 5/6 2/6 0/6 0/6 
6  6/6 6/6 6/6 6/6 6/6 5/6 2/6 0/6 0/6 
 471 
10% weight/volume homogenate was prepared using frontal cortex from a symptomatic vCJD patient (using the same homogenate as in table 1).  472 
Samples were serially 1/10 diluted (10
-2
 to 10
-10
) before being used for seeding PMCA reactions. Six individual replicates of each sample dilution 473 
were tested. The PMCA substrate was prepared using brains from transgenic mice over-expressing the ARQ variant of the sheep prion protein. 474 
Reactions were then subjected to 6 amplification rounds, each composed of 96 cycles (10s sonication-14 minutes and 50 seconds incubation at 475 
39.5°C) in a Qsonica700. After each round, (i) reaction products (1 volume) were mixed with fresh substrate (9 volumes) to seed the following 476 
round while (ii) a part of the same product was analysed by Western Blot (WB) for the presence of PK resistant PrP (PrP
res
 -antibody Sha31 477 
epitope YEDRYYRE). The number of PrP
res
 WB positive replicates corresponding to each round and each dilution are reported. 478 
 479 
  480 
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Table 3: Characteristics of the patients included in the study 481 
 482 
Patient 
Identifiant 
Diagnosis Gender 
Year of 
death 
Age at death  
Disease 
duration  
PRNP 
codon 129 
PRNP mutations 
vCJD-1 vCJD M 1999 33 years 18 months MM No mutations detected 
vCJD-2 vCJD F 2000 17 years 18 months MM No mutations detected 
vCJD-4 vCJD M 2000 26 years 10 months MM No mutations detected 
vCJD-3 vCJD M 2001 26 years 10 months MM No mutations detected 
vCJD-A Asymptomatic vCJD  F 2004 82 years N/A MV No mutations detected 
NC-1 
Not CJD (tumour, infarction, 
ischaemia) 
F 2005 85 years  N/A MM No consent for sequencing 
NC-2 
Not CJD (Alzheimer’s disease, 
infarction, ischaemia) 
F 2010 80 years N/A MM No mutations detected 
 483 
 484 
  485 
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Table 4: Results of Protein Misfolding Cyclic Amplification reactions seeded with tissue homogenate from vCJD infected and control patients  486 
  
vCJD clinical  
(Met129/Met129) 
 
vCJD preclinical  
(Met129/Val129) 
 
Non vCJD controls 
(Met129/Met129) 
Tissue  vCJD-1 vCJD-2 vCJD-3 vCJD-4  vCJD-A  NC-1 NC-2 
           
Frontal cortex  10
-8
 10
-8
 10
-8
 10
-8
  neg  neg neg 
Pituitary gland  N/A N/A N/A N/A  10
-2
  neg neg 
Trigeminal ganglia  N/A N/A N/A N/A  neg  neg neg 
Dorsal root ganglia  N/A N/A N/A N/A  neg  neg neg 
           
Cervical Lymph 
node 
 10
-5
 10
-4
 10
-4
 10
-3
  10
-4
  NA NA 
Tonsil  10
-3
 10
-4
 10
-6
 10
-3
  10
-3
  NA neg 
Appendix  10
-4
 10
-4
 10
-4
 10
-3
  10
-2
  neg neg 
Distal Ileum   10
-3
 10
-5
 10
-5
 10
-2
  10
-3
  neg neg 
Spleen  10
-4
 10
-4
 10
-5
 10
-4
  10
-3
  neg neg 
Thymus  NA 10
-3
 10
-2
 10
-2
  10
-2
  NA NA 
           
Lung  10
-2
 10
-2
 neg neg  10
-3
  neg neg 
Heart  10
-2
 10
-2
 neg neg  neg  neg neg 
Liver   10
-4
 10
-2
 10
-2
 10
-4
  10
-2
  neg neg 
           
Kidney  10
-2
 10
-3
 neg 10
-3
  neg  neg neg 
Salivary gland  10
-4
 10
-3
 10
-2
 10
-3
  10
-2
  neg neg 
           
Pancreas  10
-2
 neg 10
-2
 10
-4
  neg  neg neg 
Thyroid  10
-2
 neg 10
-2
 10
-2
  neg  neg neg 
Adrenal gland  10
-3
 10
-3
 10
-3
 10
-4
  neg  neg neg 
           
Bone marrow  10
-4
 10
-5
 10
-3
 10
-4
  neg  neg neg 
           
Skeletal muscle  10
-4
 10
-2
 neg N/A  neg  neg neg 
           
Testis  neg NA neg 10
-3
  N/A  N/A N/A 
Ovary  N/A 10
-4
 N/A N/A  N/A  N/A N/A 
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PMCA reactions were seeded with ten-fold serial dilutions of vCJD 10% tissues homogenates (10
-2
 to 10
-9
) that had been collected post mortem 487 
in symptomatic vCJD patients (vCJD-1 to vCJD-4) or an asymptomatic vCJD-infected individual (vCJD-A). At least four replicates of each 488 
sample dilution were tested in two independent PMCA runs. 489 
vCJD-1 to vCJD-4were homozygous for methionine at codon 129 of the PRNP gene. Patient vCJD-A was heterozygous (methionine/valine) at 490 
codon 129 of the PRNP gene. The PMCA substrate was prepared using brains from transgenic mice over-expressing the ARQ variant of the 491 
sheep prion protein. Reactions seeded with tissues from two non-vCJD infected control patients (NC-1 and NC-2) were included as controls. 492 
PMCA reactions were then subjected to 4 amplification rounds each comprising 96 cycles (10s sonication-14 minutes and 50 seconds incubation 493 
at 39.5°C) in a Qsonica700. The PMCA reactions were analysed by Western Blot (WB) for the presence of PK resistant PrP (PrP
res
 -antibody 494 
Sha31 epitope YEDRYYRE). The last positive dilution that resulted in a positive WB signal in at least half of the tested replicates after 4 PMCA 495 
amplification rounds is reported in the table. N/A denotes not applicable. Neg denotes negative.  496 
 497 
  498 
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Table 5: Bone marrow sample bioassay in bovine PrP expressing mice (tgBov) 499 
 500 
 
 
Transmission in tgBov 
 
Infectious titer (LD50/g) 
Mean – (CI 95%) 
case 
 Positive/inoculated 
mice 
Incubation 
(mean±SD) 
 
vCJD-1  5/5 458±37 days  10
3.05
 (10
2.62
-10
3.49
) 
vCJD-2  6/6 373±35 days   10
4.72
 (10
4.26
-10
5.18
) 
vCJD-3  4/6 504±10 days  10
2.28
 (10
1.83
-10
2.71
) 
vCJD-4  6/6 447±91 days  10
3.98
 (10
3.44
-10
4.54
) 
PBS control  0/6 >600 days  N/A 
 501 
Bone marrow from four symptomatic vCJD patients (see table 3) was inoculated intracerebrally (IC) into 6 tgBov mice (20µL per mouse). One 502 
mouse (inoculated with vCJD-1) died within the first few days following IC inoculation. Mice were euthanized when they showed clinical signs 503 
of prion infection or after 600 days post inoculation.  Mice were considered prion infected when abnormal PrP deposition was detected in brain. 504 
Infectious prion titres were estimated using the method developed by Arnold et al. (17). The model uses both the probability of survival (attack 505 
rate at each dilution) and the individual mouse incubation periods at each dilution to estimate the infectious load. Infectious titres are given as the 506 
most likely value and, in parentheses, the lower and upper limits of the 95% confidence intervals.  507 
 508 
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Figures: 509 
Figure 1: PMCA amplification of vCJD agent  510 
PMCA reactions were seeded with 1/10 dilution series of a reference vCJD brain homogenate 511 
(10% weight / volume -10
-2
 to 10
-10
 dilution). This homogenate has been endpoint titrated by 512 
bioassay in bovine PrP expressing mice (tgBov, intracerebral route – 10
7.7
 DL50/g). 513 
PMCA substrate was prepared using brains from transgenic mice over-expressing the ARQ 514 
variant of the sheep prion protein. Unseeded reactions were included as specificity control. 515 
PMCA reactions were then submitted to 6 amplification rounds each constituted with 96 516 
cycles (10s sonication-14 minutes and 50 seconds incubation at 39.5°C) in a Qsonica700. 517 
After each round, (i) reaction products (1 volume) were mixed with fresh substrate (9 518 
volumes) to seed the following round while (ii) a part of the same product was analysed by 519 
Western Blot (WB) for the presence of abnormal PK resistant PrP (PrP
res
 -antibody Sha31 520 
epitope YEDRYYRE).  521 
On each gel a scrapie in sheep isolate was used as control (WB control). 522 
 523 
Figure 2: vCJD Protein Misfolding Cyclic Amplification in peripheral tissues  524 
PMCA reactions were seeded with ten-fold dilution series of vCJD tissues homogenates (10
-2
 525 
to 10
-9
) that had been collected post mortem in vCJD-infected patient at clinical stage or 526 
preclinical stage of the disease. At least four replicates of each sample dilution were tested in 527 
two independent PMCA runs. 528 
Patients (a) vCJD-1, (b) vCJD-2, (c) vCJD-3 and (d) vCJD-4 were at clinical stage of the 529 
disease when they deceased. These four patients were homozygotes Methionine at codon 129 530 
of the PRNP gene. Patient (e) vCJD-A died while at the preclinical stage of the disease. This 531 
patient was heterozygous Methionine/Valine at codon 129 of the PRNP gene. 532 
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PMCA substrate was prepared using brains from transgenic mice over-expressing the ARQ 533 
variant of the sheep prion protein. Unseeded reactions and reaction seeded with tissues from 534 
two non-vCJD infected control patients (NC-1 and NC-2 see table 3) were included as 535 
specificity control. PMCA reactions were then subjected to 4 amplification rounds each 536 
constituted with 96 cycles (10s sonication-14 minutes and 50 seconds incubation at 39.5°C) in 537 
a Qsonica700. After each round, (i) reaction products (1 volume) were mixed with fresh 538 
substrate (9 volumes) to seed the following round while (ii) a part of the same product was 539 
analysed by Western Blot (WB) for the presence of abnormal PK resistant PrP (PrP
res
 -540 
antibody Sha31 epitope YEDRYYRE).  541 
For each round, the last dilution displaying a positive WB signal in at least half of the tested 542 
replicates is indicated on the graph. (○): round 1 - () : round 2 - (): round 3 - (): round 4. 543 
 544 
Figure 3: PrP
res
 WB detection in PMCA reactions seeded with peripheral tissues  545 
PMCA reactions were seeded with ten-fold dilution series (10
-2
 to 10
-9
) of vCJD tissues 546 
homogenates that had been collected post mortem in vCJD-infected patient at clinical stage 547 
(symptomatic vCJD case 1 to vCJD case 4) or preclinical stage of the disease (vCJD asymp.) 548 
(see table 2). Reactions seeded with tissues from two non-vCJD patients (see table 2) and 549 
unseeded PMCA reactions were included as specificity controls. 550 
Reactions were then subjected to 4 amplification rounds each constituted with 96 cycles (10s 551 
sonication-14 minutes and 50 seconds incubation at 39.5°C) in a Qsonica700.  552 
The PMCA reactions were analysed by Western Blot (WB) for the presence of abnormal PK 553 
resistant PrP (PrP
res
 -antibody Sha31 epitope YEDRYYRE). On each gel (i) a scrapie in sheep 554 
isolate and a vCJD reference isolate were used as control (WB cont.). 555 
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For the seven presented tissues (frontal cortex, appendix, lung, liver, salivary gland, pancreas 556 
and bone marrow) the dilution of the tissues homogenates used to seed the PMCA reactions is 557 
indicated below the immunoblots. 558 
 559 
560 
Page 63 of 64
ScholarOne support: (434) 964-4100
Emerging Infectious Diseases
Peer Review
 29
Figure 4: PrP
res
 detection by Western Blot (WB) and Paraffin Embedded Tissue blot 561 
(PET blot), in the brain of transgenic mice expressing the bovine-PrP (tgBov). 562 
(a) PrP
res
 WB of (i) a vCJD isolate (frontal cortex) and of tgBov mice (brain) inoculated with 563 
(ii) the same vCJD reference isolate or (iii) with bone marrow samples from vCJD affected 564 
patients( vCJD 1 to 4 see table 2)  and non vCJD control (NC-1, see table 2). On each gel a 565 
scrapie isolate (WB cont.) and a non-inoculated tgBov brain homogenate were included as 566 
controls. PrP
res
 immunodetection was carried out using Sha31 monoclonal antibody (epitope: 567 
145YEDRYYRE152) and 12B2 epitope (epitope 89WGQGG93). 568 
(b) PET blot PrP
res
 distribution in coronal section (thalamus level) of tgBov mice inoculated 569 
with a reference vCJD isolate (10% brain homogenate) or bone marrow (10% tissue 570 
homogenate) from two vCJD pati nts at clinical stage of the disease (vCJD-1 and vCJD-3 see 571 
table 2).  PrP
res
 immunodetection was carried out using Sha31 monoclonal antibody (epitope: 572 
145YEDRYYRE152 ). Bar: 120µm. 573 
 574 
Figure 5: Dose-response relationship for the incubation period and probability of 575 
infection of bovine PrP expressing mice. 576 
Data derived from an endpoint titration of 10% weight/volume frontal cortex homogenate 577 
from a vCJD affected patient in tg Bov mice (20µL intracerebral route, see table 1) were used 578 
to establish a model that estimate the infectious titre in an homogenate based on the 579 
incubation period and the probability of infection in inoculated mice (model is solid line, 580 
observed values given by crosses). 581 
 582 
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